Gene variants in the angiogenesis pathway and prostate cancer

Carcinogenesis

Volumn 33, Issue 7, 2012, Pages 1259-1269

  Amankwah, Ernest K ^a   Sellers, Thomas A ^a   Park, Jong Y ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 2; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 10; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANGIOGENESIS; CANCER GROWTH; CANCER RISK; CHROMOSOME 10Q; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOME ANALYSIS; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS;

EID: 84865173672     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs150     Document Type: Review

References (131)

1. Siegel,R. et al. (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J. Clin., 61, 212-236.
2. Lichtenstein,P. et al. (2000) Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N. Engl. J. Med., 343, 78-85.
3. Hindorff,L.A. et al. (2011) Genetic architecture of cancer and other complex diseases: lessons learned and future directions. Carcinogenesis, 32, 945-954.
4. Wiklund,F. (2010) Prostate cancer genomics: can we distinguish between indolent and fatal disease using genetic markers? Genome Med., 2, 45.
5. Varghese,J.S. et al. (2010) Genome-wide association studies in common cancers-what have we learnt? Curr. Opin. Genet. Dev., 20, 201-209.
6. Weis,S.M. et al. (2011) Tumor angiogenesis: molecular pathways and therapeutic targets. Nat. Med., 17, 1359-1370.
7. Carmeliet,P. et al. (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature, 473, 298-307.
8. Carmeliet,P. (2005) Angiogenesis in life, disease and medicine. Nature, 438, 932-936.
9. Potente,M. et al. (2011) Basic and therapeutic aspects of angiogenesis. Cell, 146, 873-887.
10. Folkman,J. (2007) Angiogenesis: an organizing principle for drug discovery? Nat. Rev. Drug Discov., 6, 273-286.
11. De Bock,K. et al. (2011) Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not? Nat. Rev. Clin. Oncol., 8, 393-404.
12. Hanahan,D. et al. (1996) Transgenic mouse models of tumour angiogenesis: the angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models. Eur. J. Cancer, 32A, 2386-2393.
13. Jain,L. et al. (2009) The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. Mol. Cancer Ther., 8, 2496-2508.
14. Tomic,T.T. et al. (2011) Castration resistant prostate cancer is associated with increased blood vessel stabilization and elevated levels of VEGF and Ang-2. Prostate, 72, 705-712.
15. Bono,A.V. et al. (2002) Microvessel density in prostate carcinoma. Prostate Cancer Prostatic Dis., 5, 123-127.
16. Borre,M. et al. (1998) Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br. J. Cancer, 78, 940-944.
17. Murphy,C. et al. (2005) Nonapical and cytoplasmic expression of interleukin-8, CXCR1, and CXCR2 correlates with cell proliferation and microvessel density in prostate cancer. Clin. Cancer Res., 11, 4117-4127.
18. Duggan,D. et al. (2007) Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J. Natl Cancer Inst., 99, 1836-1844.
19. Eeles,R.A. et al. (2009) Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat. Genet., 41, 1116-1121.
20. Eeles,R.A. et al. (2008) Multiple newly identified loci associated with prostate cancer susceptibility. Nat. Genet., 40, 316-321.
21. FitzGerald,L.M. et al. (2011) Genome-wide association study identifies a genetic variant associated with risk for more aggressive prostate cancer. Cancer Epidemiol. Biomarkers Prev., 20, 1196-1203.
22. Gudmundsson,J. et al. (2009) Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. Nat. Genet., 41, 1122-1126.
23. Gudmundsson,J. et al. (2007) Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat. Genet., 39, 631-637.
24. Gudmundsson,J. et al. (2008) Common sequence variants on 2p.15 and Xp11.22 confer susceptibility to prostate cancer. Nat. Genet., 40, 281-283.
25. Haiman,C.A. et al. (2011) Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. Nat. Genet., 43, 570-573.
26. Kote-Jarai,Z. et al. (2011) Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat. Genet., 43, 785-791.
27. Murabito,J.M. et al. (2007) A genome-wide association study of breast and prostate cancer in the NHLBI's Framingham Heart Study. BMC Med. Genet., 8 (suppl. 1), S6.
28. Nam,R.K. et al. (2011) New variants at 10q26 and 15q21 are associated with aggressive prostate cancer in a genome-wide association study from a prostate biopsy screening cohort. Cancer Biol. Ther., 12, 997-1004.
29. Penney,K.L. et al. (2010) Genome-wide association study of prostate cancer mortality. Cancer Epidemiol. Biomarkers Prev., 19, 2869-2876.
30. Schumacher,F.R. et al. (2011) Genome-wide association study identifies new prostate cancer susceptibility loci. Hum. Mol. Genet., 20, 3867-3875.
31. Sun,J. et al. (2009) Sequence variants at 22q13 are associated with prostate cancer risk. Cancer Res., 69, 10-15.
32. Takata,R. et al. (2010) Genome-wide association study identifies five new susceptibility loci for prostate cancer in the Japanese population. Nat. Genet., 42, 751-754.
33. Thomas,G. et al. (2008) Multiple loci identified in a genome-wide association study of prostate cancer. Nat. Genet., 40, 310-315.
34. Yeager,M. et al. (2007) Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat. Genet., 39, 645-649.
35. McCarron,S.L. et al. (2002) Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res., 62, 3369-3372.
36. Sfar,S. et al. (2006) Association of VEGF genetic polymorphisms with prostate carcinoma risk and clinical outcome. Cytokine, 35, 21-28.
37. Jacobs,E.J. et al. (2008) Polymorphisms in angiogenesis-related genes and prostate cancer. Cancer Epidemiol. Biomarkers Prev., 17, 972-977.
38. Langsenlehner,T. et al. (2008) Single nucleotide polymorphisms and haplotypes in the gene for vascular endothelial growth factor and risk of prostate cancer. Eur. J. Cancer, 44, 1572-1576.
39. Lin,C.C. et al. (2003) Vascular endothelial growth factor gene-460 C/T polymorphism is a biomarker for prostate cancer. Urology, 62, 374-377.
40. Fukuda,H. et al. (2007) Clinical implication of vascular endothelial growth factor T-460C polymorphism in the risk and progression of prostate cancer. Oncol. Rep., 18, 1155-1163.
41. Onen,I.H. et al. (2008) No association between polymorphism in the vascular endothelial growth factor gene at position -460 and sporadic prostate cancer in the Turkish population. Mol. Biol. Rep., 35, 17-22.
42. VanCleave,T.T. et al. (2010) Interaction among variant vascular endothelial growth factor (VEGF) and its receptor in relation to prostate cancer risk. Prostate, 70, 341-352.
43. Wang,J. et al. (2004) The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression. Clin. Cancer Res., 10, 6169-6178.
44. Ma,Z. et al. (2008) Polymorphisms of fibroblast growth factor receptor 4 have association with the development of prostate cancer and benign prostatic hyperplasia and the progression of prostate cancer in a Japanese population. Int. J. Cancer, 123, 2574-2579.
45. FitzGerald,L.M. et al. (2009) Association of FGFR4 genetic polymorphisms with prostate cancer risk and prognosis. Prostate Cancer Prostatic Dis., 12, 192-197.
46. Xu,W. et al. (2010) FGFR4 transmembrane domain polymorphism and cancer risk: a meta-analysis including 8555 subjects. Eur. J. Cancer, 46, 3332-3338.
47. Xu,B. et al. (2011) FGFR4 Gly388Arg polymorphism contributes to prostate cancer development and progression: a meta-analysis of 2618 cases and 2305 controls. BMC Cancer, 11, 84.
48. Veikkola,T. et al. (2000) Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res., 60, 203-212.
49. Borre,M. et al. (2000) Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting. Clin. Cancer Res., 6, 1882-1890.
50. Botelho,F. et al. (2010) VEGF and prostatic cancer: a systematic review. Eur. J. Cancer Prev., 19, 385-392.
51. Stevens,A. et al. (2003) Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res., 63, 812-
52. Lancaster, J.R. Jr et al. (2006) Tumors face NO problems? Cancer Res., 66, 6459-6462.
53. Mocellin,S. et al. (2007) Nitric oxide, a double edged sword in cancer biology: searching for therapeutic opportunities. Med. Res. Rev., 27, 317-
54. Uotila,P. et al. (2001) Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer. Urol. Res., 29, 23-28.
55. Klotz,T. et al. (1998) Selective expression of inducible nitric oxide synthase in human prostate carcinoma. Cancer, 82, 1897-1903.
56. Tong,X. et al. (2004) eNOS protects prostate cancer cells from TRAILinduced apoptosis. Cancer Lett., 210, 63-71.
57. Lee,K.M. et al. (2009) Nitric oxide synthase gene polymorphisms and prostate cancer risk. Carcinogenesis, 30, 621-625.
58. Wartenberg,M. et al. (2003) Reactive oxygen species-mediated regulation of eNOS and iNOS expression in multicellular prostate tumor spheroids. Int. J. Cancer, 104, 274-282.
59. Medeiros,R.M. et al. (2002) Endothelial nitric oxide synthase gene polymorphisms and genetic susceptibility to prostate cancer. Eur. J. Cancer Prev., 11, 343-350.
60. Ropiquet,F. et al. (2000) Increased expression of fibroblast growth factor 6 in human prostatic intraepithelial neoplasia and prostate cancer. Cancer Res., 60, 4245-4250.
61. Wesche,J. et al. (2011) Fibroblast growth factors and their receptors in cancer. Biochem. J., 437, 199-213.
62. Streit,S. et al. (2006) FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients. Br. J. Cancer, 94, 1879-1886.
63. Spinola,M. et al. (2005) Functional FGFR4 Gly388Arg polymorphism predicts prognosis in lung adenocarcinoma patients. J. Clin. Oncol., 23, 7307-7311.
64. Ho,C.K. et al. (2010) FGFR4 Gly388Arg polymorphism and prostate cancer risk in Scottish men. Prostate Cancer Prostatic Dis., 13, 94-96.
65. Zhu,B. et al. (2005) Transforming growth factor beta and prostate cancer. Cancer Treat. Res., 126, 157-173.
66. Kambhampati,S. et al. (2005) Growth factors involved in prostate carcinogenesis. Front. Biosci., 10, 1355-1367.
67. Yokota,M. et al. (2000) Association of a T29->C polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to myocardial infarction in Japanese. Circulation, 101, 2783-2787.
68. Grainger,D.J. et al. (1999) Genetic control of the circulating concentration of transforming growth factor type beta1. Hum. Mol. Genet., 8, 93-97.
69. Ewart-Toland,A. et al. (2004) A gain of function TGFB1 polymorphism may be associated with late stage prostate cancer. Cancer Epidemiol. Biomarkers Prev., 13, 759-764.
70. Brand,T.C. et al. (2008) Association of polymorphisms in TGFB1 and prostate cancer prognosis. J. Urol., 179, 754-758.
71. Faria,P.C. et al. (2007) Transforming growth factor-beta 1 gene polymorphisms and expression in the blood of prostate cancer patients. Cancer Invest., 25, 726-732.
72. Kang,D. et al. (2007) Lack of association of transforming growth factorbeta1 polymorphisms and haplotypes with prostate cancer risk in the prostate, lung, colorectal, and ovarian trial. Cancer Epidemiol. Biomarkers Prev., 16, 1303-1305.
73. Li,Z. et al. (2004) Increased risk of prostate cancer and benign prostatic hyperplasia associated with transforming growth factor-beta 1 gene polymorphism at codon10. Carcinogenesis, 25, 237-240.
74. Meyer,A. et al. (2009) TGFB1 gene polymorphism Leu10Pro (c.29T.C), prostate cancer incidence and quality of life in patients treated with brachytherapy. World J. Urol., 27, 371-377.
75. Wei,B.B. et al. (2010) TGFbeta1 T29C polymorphism and cancer risk: a meta-analysis based on 40 case-control studies. Cancer Genet. Cytogenet., 196, 68-75.
76. Wu,Y. et al. (2010) TNF-alpha/NF-kappaB/Snail pathway in cancer cell migration and invasion. Br. J. Cancer, 102, 639-644.
77. Johnston,D.A. et al. (2009) TNF induction of jagged-1 in endothelial cells is NFkappaB-dependent. Gene, 435, 36-44.
78. Balkwill,F. (2009) Tumour necrosis factor and cancer. Nat. Rev. Cancer, 9, 361-371.
79. Wang,J. et al. (2011) Tumour necrosis factor alpha-308G/A polymorphism and risk of the four most frequent cancers: a meta-analysis. Int. J. Immunogenet., 38, 311-320.
80. Wang,M.H. et al. (2009) Association of IL10 and other immune responseand obesity-related genes with prostate cancer in CLUE II. Prostate, 69, 874-885.
81. Moore,S.C. et al. (2009) Adipokine genes and prostate cancer risk. Int. J. Cancer, 124, 869-876.
82. Kesarwani,P. et al. (2009) Polymorphisms in tumor necrosis factor-A gene and prostate cancer risk in North Indian cohort. J. Urol., 182, 2938-2943.
83. Zabaleta,J. et al. (2008) Interactions of cytokine gene polymorphisms in prostate cancer risk. Carcinogenesis, 29, 573-578.
84. Danforth,K.N. et al. (2008) TNF polymorphisms and prostate cancer risk. Prostate, 68, 400-407.
85. Wu,H.C. et al. (2004) p.53 gene codon 72 polymorphism but not tumor necrosis factor-alpha gene is associated with prostate cancer. Urol. Int., 73, 41-46.
86. Zabaleta,J. et al. (2009) Cytokine genetic polymorphisms and prostate cancer aggressiveness. Carcinogenesis, 30, 1358-1362.
87. Dunn,I.F. et al. (2000) Growth factors in glioma angiogenesis: FGFs, PDGF, EGF, and TGFs. J. Neurooncol., 50, 121-137.
88. Teixeira,A.L. et al. (2008) Genetic polymorphism in EGF is associated with prostate cancer aggressiveness and progression-free interval in androgen blockade-treated patients. Clin. Cancer Res., 14, 3367-3371.
89. Majmundar,A.J. et al. (2010) Hypoxia-inducible factors and the response to hypoxic stress. Mol. Cell, 40, 294-309.
90. Chau,C.H. et al. (2005) Polymorphism in the hypoxia-inducible factor 1alpha gene may confer susceptibility to androgen-independent prostate cancer. Cancer Biol. Ther., 4, 1222-1225.
91. Li,H. et al. (2007) Hypoxia-inducible factor-1alpha (HIF-1alpha) gene polymorphisms, circulating insulin-like growth factor binding protein (IGFBP)-3 levels and prostate cancer. Prostate, 67, 1354-1361.
92. Foley,R. et al. (2009) The HIF-1alpha C1772T polymorphism may be associated with susceptibility to clinically localised prostate cancer but not with elevated expression of hypoxic biomarkers. Cancer Biol. Ther., 8, 118-124.
93. Willis,L.M. et al. (2011) Angiotensin receptor blockers and angiogenesis: clinical and experimental evidence. Clin Sci (Lond), 120, 307-319.
94. Ruiter,R. et al. (2011) The ACE insertion/deletion polymorphism and risk of cancer, a review and meta-analysis of the literature. Curr. Cancer Drug Targets, 11, 421-430.
95. Sierra Diaz,E. et al. (2009) Angiotensin-converting enzyme insertion/deletion and angiotensin type 1 receptor A1166C polymorphisms as genetic risk factors in benign prostatic hyperplasia and prostate cancer. J. Renin Angiotensin Aldosterone Syst., 10, 241-246.
96. van der Knaap,R. et al. (2008) Renin-angiotensin system inhibitors, angiotensin I-converting enzyme gene insertion/deletion polymorphism, and cancer: the Rotterdam Study. Cancer, 112, 748-757.
97. Yigit,B. et al. (2007) Effects of ACE I/D polymorphism on prostate cancer risk, tumor grade and metastatis. Anticancer Res., 27, 933-936.
98. Wang,X. et al. (2011) Angiotensin-converting enzyme insertion/deletion polymorphism and the risk of prostate cancer in the Han population of China. Med. Oncol. [Published online ahead of print 28 Aug 2011] http:// www.ncbi.nlm.nih.gov/pubmed/21874567 (12 September 2011, date last accessed).
99. Rundhaug,J.E. (2005) Matrix metalloproteinases and angiogenesis. J. Cell. Mol. Med., 9, 267-285.
100. Deryugina,E.I. et al. (2010) Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: contrasting, overlapping and compensatory functions. Biochim. Biophys. Acta., 1803, 103-120.
101. Martin,M.D. et al. (2007) The other side of MMPs: protective roles in tumor progression. Cancer Metastasis Rev., 26, 717-724.
102. Tower,G.B. et al. (2003) The 2G single nucleotide polymorphism (SNP) in the MMP-1 promoter contributes to high levels of MMP-1 transcription in MCF-7/ADR breast cancer cells. Breast Cancer Res. Treat., 82, 75-82.
103. Rutter,J.L. et al. (1998) A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res., 58, 5321-5325.
104. Tsuchiya,N. et al. (2009) Clinical significance of a single nucleotide polymorphism and allelic imbalance of matrix metalloproteinase-1 promoter region in prostate cancer. Oncol. Rep., 22, 493-499.
105. Albayrak,S. et al. (2007) Role of MMP-1 1G/2G promoter gene polymorphism on the development of prostate cancer in the Turkish population. Urol. Int., 79, 312-315.
106. Sfar,S. et al. (2007) TSP1 and MMP9 genetic variants in sporadic prostate cancer. Cancer Genet. Cytogenet., 172, 38-44.
107. Gil Ugarteburu,R. et al. (2010) Matrix metalloproteinase-9 polymorphisms in the diagnosis of prostate cancer. A preliminary experience. Arch. Esp. Urol., 63, 125-132.
108. Lehrer,S. et al. (2004) Serum interleukin-8 is elevated in men with prostate cancer and bone metastases. Technol. Cancer Res. Treat., 3, 411.
109. Michaud,D.S. et al. (2006) Genetic polymorphisms of interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and risk of prostate cancer. Cancer Res., 66, 4525-4530.
110. Yang,H.P. et al. (2006) Genetic variation in interleukin 8 and its receptor genes and its influence on the risk and prognosis of prostate cancer among Finnish men in a large cancer prevention trial. Eur. J. Cancer Prev., 15, 249-253.
111. Kalkunte,S. et al. (2011) Vascular IL-10: a protective role in preeclampsia. J. Reprod. Immunol., 88, 165-169.
112. Mosser,D.M. et al. (2008) Interleukin-10: new perspectives on an old cytokine. Immunol. Rev., 226, 205-218.
113. Kesarwani,P. et al. (2009) IL-10-1082 G.A: a risk for prostate cancer but may be protective against progression of prostate cancer in North Indian cohort. World J. Urol., 27, 389-396.
114. Faupel-Badger,J.M. et al. (2008) Association of IL-10 polymorphisms with prostate cancer risk and grade of disease. Cancer Causes Control, 19, 119-124.
115. Liu,J. et al. (2010) Association of genetic polymorphisms in the interleukin-10 promoter with risk of prostate cancer in Chinese. BMC Cancer, 10
116. Eder,T. et al. (2007) Interleukin-10 [ATA] promoter haplotype and prostate cancer risk: a population-based study. Eur. J. Cancer, 43, 472-475.
117. Shao,N. et al. (2011) IL-10 polymorphisms and prostate cancer risk: a meta-analysis. Prostate Cancer Prostatic Dis., 14, 129-135.
118. Zou,Y.F. et al. (2011) Lack of association of IL-10 gene polymorphisms with prostate cancer: evidence from 11,581 subjects. Eur. J. Cancer, 47, 1072-1079.
119. Lin,H.C. et al. (2009) Influence of cytokine gene polymorphisms on prostate-specific antigen recurrence in prostate cancer after radical prostatectomy. Urol. Int., 83, 463-470.
120. Liu,Y. et al. (2007) Genetic polymorphisms of the interleukin-18 gene and risk of prostate cancer. DNA Cell Biol., 26, 613-618.
121. O'Reilly,M.S. et al. (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 88, 277-285.
122. Yokoyama,Y. et al. (2000) Effect of endostatin on spontaneous tumorigenesis of mammary adenocarcinoma in a transgenic mouse model. Cancer Res., 60, 4362-4365.
123. Perletti,G. et al. (2000) Antitumor activity of endostatin against carcinogeninduced rat primary mammary tumors. Cancer Res., 60, 1793-1796.
124. Yoon,S.S. et al. (1999) Mouse endostatin inhibits the formation of lung and liver metastases. Cancer Res., 59, 6251-6256.
125. Hasle,H. et al. (2000) Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet, 355, 165-169.
126. Iughetti,P. et al. (2001) A polymorphism in endostatin, an angiogenesis inhibitor, predisposes for the development of prostatic adenocarcinoma. Cancer Res., 61, 7375-7378.
127. Macpherson,G.R. et al. (2004) Genotyping and functional analysis of the D104N variant of human endostatin. Cancer Biol. Ther., 3, 1298-1303.
128. Li,H.C. et al. (2005) Endostatin polymorphism 4349G/A(D104N) is not associated with aggressiveness of disease in prostate [corrected] cancer. Dis. Markers, 21, 37-41.
129. Mucci,L.A. et al. (2009) Polymorphism in endostatin, an angiogenesis inhibitor, and prostate cancer risk and survival: a prospective study. Int. J. Cancer, 125, 1143-1146.
130. Teixeira,A.L. et al. (2009) Combined analysis of EGF+61G.A and TGFB1+869T.C functional polymorphisms in the time to androgen independence and prostate cancer susceptibility. Pharmacogenomics J., 9, 341-346.
131. Sfar,S. et al. (2009) Combined effects of the angiogenic genes polymorphisms on prostate cancer susceptibility and aggressiveness. Mol. Biol. Rep., 36, 37-45.